NEW YORK, Feb. 18, 2013 Reportlinker.com announces that a new market research report is available in its catalogue:
Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus.
This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted, which in turn are influenced by vaccine mechanism of action and vaccinee serostatus.
THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL
Executive summaryCMV preconception vaccine: available market ($000s) to 2035CMV transplant vaccine: available market ($000s) to 2035CMV preconception vaccine: demand (000s doses) to 2035CMV transplant vaccine: demand (000s doses) to 2035CMV vaccine: modelling assumptions/rationaleThe role of CMV vaccine(s)Target populations: CMV preconception vaccineTarget populations: CMV transplant vaccineTarget groups by serological risk profilePricing: CMV preconception vaccinePricing: CMV transplant vaccineTarget product profile: CMV preconception vaccineTarget product profile: CMV transplant vaccineKey commercial model assumptions: preconception vaccineKey commercial model assumptions: transplant vaccineMarkets included in the modelModel forecast comparisons: June 2010 v currentCMV vaccines: R&D pipelineCompetitor landscape: overviewVical/Astellas: TransVax and CyMVectinGSK: preconception CMV vaccineNovartis/AlphaVax: alphavirus replicon CMV vaccineSanofi Pasteur: CMV gB vaccineOther vaccine candidatesVaccine pipeline summaryEstimated launch datesCMV: review of current epidemiologyEpidemiology: transplantsEpidemiology: congenital CMV infectionMethodology: HSCTs populations (by age and serostatus)Methodology: solid organ transplant populations (by age and serostatus)Methodology: preconception vaccinePreconception vaccine: comparison of "low" versus "high" coverage scenariosReferences/bibliographyAbout VacZine AnalyticsDisclaimerPAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based)Title sheetScenarion definitionsGRAND SUMMARY CHARTSCHARTS VALUECHARTS VOLUMECHARTS VOLUME – HIGHVALUE SUMMARYVOLUME SUMMARYPreconception vaccine - femalesCountry volume/population sheetsUSCanadaUKGermanyFranceSpainItalyOther EUJapanTransplant vaccine - femalesCountry volume/population sheetsUSCanadaUKGermanyFranceSpainItalyOther EUJapanSource materialHSCTs by serostatusForecast HSCTsForecast HSCTsKidney and Liver TX baseForecast Kidney TXForecast liver TxSOT by serostatusPopulationsBack pageAbout VacZine AnalyticsDisclaimer
To order this report:: MarketVIEW: Cytomegalovirus vaccines
Intl: +1 805-652-2626